TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05157074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Drumming Music Therapy
Description: All 24 Armstrong Rhythm Cycle™ sessions is conducted in a circle to ensure maximum line of sight for each participant. A variety of diverse percussion instruments ranging from hand drums, stick drums, shakers, and rhythm sticks are available as well as adaptive measures to address limited physical functioning. Instrument choice is dependent on ease of use for the level of the physical ability, skill development needs, and personal choice. Participants are informed that they are free to use the same instrument for the duration of each session or to switch instruments at any time.~Utilizing the five components of The Armstrong Rhythm Method, this protocol guides participants through three phases to achieve rhythmic skill development and group cohesion for their therapeutic benefit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Drumming Music Therapy
Description: All 24 Armstrong Rhythm Cycle™ sessions is conducted in a circle to ensure maximum line of sight for each participant. A variety of diverse percussion instruments ranging from hand drums, stick drums, shakers, and rhythm sticks are available as well as adaptive measures to address limited physical functioning. Instrument choice is dependent on ease of use for the level of the physical ability, skill development needs, and personal choice. Participants are informed that they are free to use the same instrument for the duration of each session or to switch instruments at any time.~Utilizing the five components of The Armstrong Rhythm Method, this protocol guides participants through three phases to achieve rhythmic skill development and group cohesion for their therapeutic benefit.
Study: NCT00297193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous haematopoietic stem cell transplant
Description: All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous haematopoietic stem cell transplant
Description: All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.
Study: NCT00954733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arterial blood draw
Description: One arterial blood draw
Study: NCT01378910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unique
Description: Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
Study: NCT01457105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiography (ERC) (ComVi biliary stent)
Description: Metal stents placement in the main biliary duct during ERC
Study: NCT02848716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery followed with chemoradiation
Description: Patients with negative paraaortic lymph nodes will be managed with external beam radiotherapy to the pelvis (as defined by the surgical clips applied at the lower limit of the paraaortic node dissection) at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy (High Dose Rate (DR), Low DR or Pulse DR) with intent to cure.~Patients with metastatic disease to paraaortic lymph nodes will receive extended-field external beam radiotherapy followed by intracavitary brachytherapy with intent to cure. Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy (in the 2 sub groups above) will be given with definitive radiation therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemoradiation
Description: patients with negative paraaortic lymph nodes on PET imaging will be managed with external beam radiotherapy to the pelvis at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy with intent to cure (HDR, LDR or PDR). Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy will be given with definitive radiation therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiation
Study: NCT04230655

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low energy diet using meal replacements
Description: The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low energy diet using meal replacements
Description: The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-based group treatment
Description: All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based group treatment
Description: All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants.
Study: NCT00981929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole, losartan, caffeine
Description: 20 mg omeprazole 25 mg losartan 200 mg caffeine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol, omeprazole, losartan, caffeine
Description: 50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
Study: NCT04230655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intragastric balloon
Description: An IGB (Orbera IGB, Apollo Endosurgery Inc., Austin, Texas, (CE certified)) is set in place endoscopically by a gastroenterologist at Örebro University Hospital, Region Örebro county, and is left in the stomach for 6 months. A proton-pump inhibitor is prescribed to counteract an increased risk to develop a gastric ulcer. During the first 2 weeks, dietary adjustments are necessary to adapt to the IGB. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended identical to the control group. The IGB is removed endoscopically after 6 months IGB treatment.
Study: NCT03775226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChampioNIR® SFA Stent
Description: The ChampioNIR® SFA Stent is composed of a Nitinol alloy structure with an elastomeric micro-fiber mesh and is designed specifically to be used in the peripheral vasculature. The stent is characterized by high flexibility, strong radial support and high resistance to fractures, as well as high deliverability and precise positioning.
Study: NCT01350505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White light exposure
Description: \~200 lux of broad spectrum white light

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dim white light exposure
Description: \~28 lux of broad spectrum white light

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very dim white light exposure
Description: \<0.5 lux of broad spectrum white light

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dim orange light exposure
Description: \~28 lux of orange light
Study: NCT03528174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Control system (APC)
Description: This intervention is a single hormone closed loop system including a Nexus 5 smart phone, two tslim insulin pumps, a Dexcom G5 CGM and two PDT glucose sensing cannulas that together make up a new experimental, investigational device system. The algorithm included in the APC is an automated version of the Fading Memory Proportional Derivative (FMPD) insulin and glucagon control algorithm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacific Diabetes Technologies CGM Insulin Infusion system
Description: An integrated combination CGM/insulin infusion system
Study: NCT02263001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular therapy for treatment of musculoskeletal pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care therapy consists of over-the-counter and prescribed pharmacotherapy
Study: NCT01295723

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Whole Breast Radiation Therapy
Description: Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)~* Single reference dose per fraction: 2.7 Gy (ICRU)~* Number of fractions: 15~* Number of fractions per week: 5~* Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)~* Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Electron Radiation Therapy
Description: Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
Study: NCT01054573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: 750 mg orally every 8 hours (q8h) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon (Peg-IFN) alfa-2a
Description: 180 microgram (mcg) by subcutaneous injection once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: 1,000 or 1,200 mg/day (weight based) orally twice daily for 48 weeks.
Study: NCT04310917

Intervention type: OTHER
Group type: OTHER
Intervention: blood lipoprotein (a) test
Description: research specific blood sample
Study: NCT03040921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine transposition.
Description: Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
Study: NCT04651400

Intervention type: DRUG
Intervention: Antithrombin III
Description: Antithrombin III
Study: NCT00905814

Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)

Intervention type: DRUG
Group type: OTHER
Intervention: AG-103736
Description: single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
Study: NCT02654457

Intervention type: PROCEDURE
Intervention: Women with Breast Cancer
Description: IVD Study

Intervention type: PROCEDURE
Intervention: Women with Breast Cancer
Description: IVD Study

Intervention type: PROCEDURE
Intervention: Women with Breast Cancer
Description: IVD Study
Study: NCT01282697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined administration of irinotecan and rapamycin
Description: This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
Study: NCT01183013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 15 mg
Description: Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 45 mg
Description: Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
Study: NCT04658823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOV-12020 (Palm tocotrienols complex)
Description: Oral Softgel capsule containing mixed tocotrienols and tocopherol with enhanced absorption delivery system; 1 capsule twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Softgel capsule containing soybean oil; 1 capsule twice daily
Study: NCT04402164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst appliance
Description: telescopic appliance for mandibular advancement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst appliance
Description: telescopic appliance for mandibular advancement
Study: NCT02283359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor is a potent slowly reversible covalent Selective Inhibitor of Nuclear Export (SINE) that specifically blocks the karyopherin protein Exportin 1 or XPO1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan is a topoisomerase inhibitor and is approved by FDA to treat colorectal cancer. It is administered intravenously.
Study: NCT02335151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Apply desflurane as anesthetic
Study: NCT02566798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extract of grape and olive
Description: Patients are taking capsules of OleograpeSEED 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7
Study: NCT02914314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: oral suspension.
Study: NCT02413463

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: augmented recession
Description: medial rectus muscle recession using augmented formula ( average of the distance angle with correction and the near angle without correction)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Faden
Description: medial rectus muscle recession (using the distance angle with correction) with posterior scleral fixation( Faden)
Study: NCT02006875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.
Study: NCT04146896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-2925 50 mg
Description: NYX-2925 administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally
Study: NCT02835846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen Cream
Description: Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram) and instructed to use 0.5 grams with an applicator twice weekly for 12 weeks.
Study: NCT04210219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64264681
Description: JNJ-64264681 capsule will be administered orally.
Study: NCT03586661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study: NCT03258580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medoc thermal stimulator
Description: Heat pain stimulation for substudy 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric shock stimulator
Description: Electric pain stimulation for substudy 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold water bath
Description: Cold pain stimulation for substudy 1

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain assessment performance feedback
Description: Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.
Study: NCT02609776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
Study: NCT03767244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo oral tablets daily.
Study: NCT04397276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70218902
Description: JNJ-70218902 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70218902
Description: JNJ-70218902 will be administered.
Study: NCT04175600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Selexipag tablet will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets will be administered orally.
Study: NCT02566668

Intervention type: OTHER
Intervention: 1 year Observational Follow-up
Description: Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.

Intervention type: OTHER
Intervention: 1 year Observational Follow-up
Description: Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
Study: NCT04047251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10850 Topotecan Liposome Injection
Description: FF-10850 to be diluted and infused over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10850 Topotecan Liposome Injection
Description: FF-10850 to be diluted and infused over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10850 Topotecan Liposome Injection
Description: FF-10850 to be diluted and infused over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10850 Topotecan Liposome Injection
Description: FF-10850 to be diluted and infused over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10850 Topotecan Liposome Injection
Description: FF-10850 to be diluted and infused over 60 minutes.
Study: NCT03104491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Inotuzumab ozogamicin, IV, 28 day cycles~Phase 1 dosages:~Dose Level -2 (0.1 mg/m\^2)~Dose Level -1 (0.2 mg/m\^2)~Dose Level 0 (0.3 mg/m\^2)~Dose Level 1 (0.4 mg/m\^2)~Dose Level 2 (0.5 mg/m\^2)~Dose Level 3 (0.6 mg/m\^2)
Study: NCT03291028

Intervention type: BIOLOGICAL
Intervention: Immune checkpoint inhibitor targeting PD1
Description: RCC and UC patients treated with immune checkpoint blockade
Study: NCT01320943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop TDF
Description: Participants will stop TDF therapy
Study: NCT01108393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine A
Description: Agomelatine 25 mg film-coated tablet~Agomelatine 2x25mg film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo